{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T13:17:19Z","timestamp":1762089439101,"version":"build-2065373602"},"reference-count":11,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T00:00:00Z","timestamp":1687132800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Cancer Res Clin Oncol"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1007\/s00432-023-04995-6","type":"journal-article","created":{"date-parts":[[2023,6,19]],"date-time":"2023-06-19T16:01:40Z","timestamp":1687190500000},"page":"11025-11030","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["SARS-CoV-2 Omicron BA.5.2-infection and COVID-19 in persons with chronic myeloid leukaemia"],"prefix":"10.1007","volume":"149","author":[{"given":"Fang","family":"Cheng","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hang","family":"Xiang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert Peter","family":"Gale","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Siyi","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiao","family":"Qu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hao","family":"Guo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qiubai","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yanli","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Weiming","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,6,19]]},"reference":[{"issue":"11","key":"4995_CR1","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1021\/acs.jcim.1c00524","volume":"61","author":"S Banerjee","year":"2021","unstructured":"Banerjee S, Yadav S, Banerjee S, Fakayode SO, Parvathareddy J, Reichard W et al (2021) Drug repurposing to identify nilotinib as a potential SARS-CoV-2 main protease inhibitor: insights from a computational and in vitro study. J Chem Inf Model 61(11):5469\u20135483. https:\/\/doi.org\/10.1021\/acs.jcim.1c00524","journal-title":"J Chem Inf Model"},{"issue":"7","key":"4995_CR2","doi-asserted-by":"publisher","first-page":"1676","DOI":"10.1177\/1078155220953198","volume":"26","author":"S Ba\u015fc\u0131","year":"2020","unstructured":"Ba\u015fc\u0131 S, Ata N, Altunta\u015f F, Yi\u011feno\u011flu TN, Dal MS, Korkmaz S et al (2020) Outcome of COVID-19 in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitors. J Oncol Pharm Pract 26(7):1676\u20131682. https:\/\/doi.org\/10.1177\/1078155220953198","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"4995_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1111\/bjh.17890","volume":"196","author":"M Breccia","year":"2022","unstructured":"Breccia M, Abruzzese E, Accurso V, Attolico I, Barulli S, Bergamaschi M et al (2022) COVID-19 infection in chronic myeloid leukaemia after one year of the pandemic in Italy. A Campus CML report. Br J Haematol 196(3):559\u2013565. https:\/\/doi.org\/10.1111\/bjh.17890","journal-title":"Br J Haematol"},{"issue":"8","key":"4995_CR4","doi-asserted-by":"publisher","first-page":"4885","DOI":"10.1128\/aac.03036-14","volume":"58","author":"J Dyall","year":"2014","unstructured":"Dyall J, Coleman CM, Hart BJ, Venkataraman T, Holbrook MR, Kindrachuk J et al (2014) Repurposing of clinically developed drugs for treatment of Middle East respiratory syndrome coronavirus infection. Antimicrob Agents Chemother 58(8):4885\u20134893. https:\/\/doi.org\/10.1128\/aac.03036-14","journal-title":"Antimicrob Agents Chemother"},{"issue":"4","key":"4995_CR5","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1038\/s41375-020-0776-2","volume":"34","author":"A Hochhaus","year":"2020","unstructured":"Hochhaus A, Baccarani M, Silver RT, Schiffer C, Apperley JF, Cervantes F et al (2020) European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia. Leukemia 34(4):966\u2013984. https:\/\/doi.org\/10.1038\/s41375-020-0776-2","journal-title":"Leukemia"},{"issue":"9","key":"4995_CR6","doi-asserted-by":"publisher","first-page":"1933","DOI":"10.1038\/s41591-022-01887-z","volume":"28","author":"JA Lewnard","year":"2022","unstructured":"Lewnard JA, Hong VX, Patel MM, Kahn R, Lipsitch M, Tartof SY (2022) Clinical outcomes associated with SARS-CoV-2 Omicron (B.1.1.529) variant and BA.1\/BA.1.1 or BA.2 subvariant infection in Southern California. Nat Med 28(9):1933\u20131943. https:\/\/doi.org\/10.1038\/s41591-022-01887-z","journal-title":"Nat Med"},{"issue":"7","key":"4995_CR7","doi-asserted-by":"publisher","first-page":"1799","DOI":"10.1038\/s41375-020-0853-6","volume":"34","author":"W Li","year":"2020","unstructured":"Li W, Wang D, Guo J, Yuan G, Yang Z, Gale RP et al (2020) COVID-19 in persons with chronic myeloid leukaemia. Leukemia 34(7):1799\u20131804. https:\/\/doi.org\/10.1038\/s41375-020-0853-6","journal-title":"Leukemia"},{"issue":"10335","key":"4995_CR8","doi-asserted-by":"publisher","first-page":"1618","DOI":"10.1016\/s0140-6736(22)00327-0","volume":"399","author":"C Menni","year":"2022","unstructured":"Menni C, Valdes AM, Polidori L, Antonelli M, Penamakuri S, Nogal A et al (2022) Symptom prevalence, duration, and risk of hospital admission in individuals infected with SARS-CoV-2 during periods of omicron and delta variant dominance: a prospective observational study from the ZOE COVID Study. Lancet 399(10335):1618\u20131624. https:\/\/doi.org\/10.1016\/s0140-6736(22)00327-0","journal-title":"Lancet"},{"issue":"10","key":"4995_CR9","doi-asserted-by":"publisher","first-page":"e737","DOI":"10.1016\/s2352-3026(20)30251-9","volume":"7","author":"F Passamonti","year":"2020","unstructured":"Passamonti F, Cattaneo C, Arcaini L, Bruna R, Cavo M, Merli F et al (2020) Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study. Lancet Haematol 7(10):e737\u2013e745. https:\/\/doi.org\/10.1016\/s2352-3026(20)30251-9","journal-title":"Lancet Haematol"},{"key":"4995_CR10","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1016\/j.ijid.2021.11.040","volume":"114","author":"E Petersen","year":"2022","unstructured":"Petersen E, Ntoumi F, Hui DS, Abubakar A, Kramer LD, Obiero C et al (2022) Emergence of new SARS-CoV-2 Variant of Concern Omicron (B.1.1.529)\u2014highlights Africa\u2019s research capabilities, but exposes major knowledge gaps, inequities of vaccine distribution, inadequacies in global COVID-19 response and control efforts. Int J Infect Dis 114:268\u2013272. https:\/\/doi.org\/10.1016\/j.ijid.2021.11.040","journal-title":"Int J Infect Dis"},{"key":"4995_CR11","volume-title":"Clinical Management of COVID-19 Living Guideline","author":"WHO","year":"2022","unstructured":"WHO (2022) WHO Guidelines Approved by the Guidelines Review Committee. Clinical Management of COVID-19 Living Guideline. World Health Organization"}],"container-title":["Journal of Cancer Research and Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04995-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00432-023-04995-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00432-023-04995-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,29]],"date-time":"2023-08-29T09:06:55Z","timestamp":1693300015000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00432-023-04995-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,19]]},"references-count":11,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["4995"],"URL":"https:\/\/doi.org\/10.1007\/s00432-023-04995-6","relation":{},"ISSN":["0171-5216","1432-1335"],"issn-type":[{"type":"print","value":"0171-5216"},{"type":"electronic","value":"1432-1335"}],"subject":[],"published":{"date-parts":[[2023,6,19]]},"assertion":[{"value":"20 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 June 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"RPG is a consultant to Antengene Biotech LLC, Ascentage Pharma Group and NexImmune Inc.; Medical Director, FFF Enterprises Inc.; Board of Directors: Russian Foundation for Cancer Research Support; and Scientific Advisory Boards, Nanexa AB and StemRad Ltd.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the Institutional Ethics Committee of Tongji Medical College, Huazhong University of Science and Technology (Wuhan, China) ([2023] 0065). The requirement for written informed consent was waived.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement"}}]}}